HOME >> BIOLOGY >> NEWS
RIT researchers developing 'micropump' for hearing-loss treatments

l engineering and micoelectromechanical systems.

The project is expected to provide a detailed understanding of acceptable dose and timing profiles for intracochlear drug delivery in mice without detriment to cochlear function. The technology is scaleable to use in humans and may be particularly useful in pediatrics.

Robert D. Frisina, a professor and associate chair of otolaryngology and professor of biomedical engineering and neurobiology and anatomy at the University of Rochester Medical Center, is serving as research mentor. Frisina is also distinguished researcher in biological sciences in RIT's College of Science and professor of communication sciences and associate director of the International Center for Hearing and Speech Research at the National Technical Institute for the Deaf at RIT.

"Although some people are helped with hearing aids, the majority of those with hearing loss or hearing-related balance disorders go untreated," Frisina says. "Future biomedical interventions will be aimed at treating the underlying biological problems that cause permanent sensorineural hearing loss rather than trying to amplify and filter incoming sounds with hearing aids.

"A critical step for implementing research aimed at repairing or restoring nerve cells that are damaged or missing in the inner ear is to develop more precise, calibrated micropumps for delivering chemotherapeutic, gene-therapy or stem-cell therapeutic agents, first for animal research, then for clinical trials. This project is a critical step forward in developing microfabricated pumps. Longer-term goals include developing and testing inner ear micropumps for clinical applications to treat human inner-ear hearing and balance problems."


'"/>

Contact: Michael Saffran
mjsuns@rit.edu
585-475-5697
Rochester Institute of Technology
12-Feb-2007


Page: 1 2

Related biology news :

1. Innovative tagging technique may help researchers better protect fish stocks
2. Penn researchers discover how key protein stops inflammation
3. ASU researchers partner with UOP to make biofuel for military jets a reality
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Penn researchers discover pathway that eliminates genetic defects in red blood cells
6. U-M researchers find family of on switches that cause prostate cancer
7. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
8. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
9. MGH researchers confirm that bone marrow restores fertility in female mice
10. Smithsonians National Zoo researchers use electronic eggs to help save threatened species
11. U-M researchers identify gene involved in breast cancer

Post Your Comments:
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... 17, 2014   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, announced today its presentation at ... San Francisco, CA. ... Officer, will present on Monday, January 12, 2015, at ... be webcast live and may be accessed from the ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: